LivaNova Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LivaNova stock.
View analyst ratings for LivaNova or view top-rated stocks.

Wall Street analysts have given LivaNova a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but LivaNova wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

LivaNova saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,620,000 shares, an increase of 20.2% from the July 29th total of 2,180,000 shares. Based on an average trading volume of 356,600 shares, the days-to-cover ratio is presently 7.3 days.
View LivaNova's Short Interest.

LivaNova is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for LivaNova.

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday, July, 28th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.19. The business earned $264.50 million during the quarter, compared to analysts' expectations of $241.73 million. LivaNova had a negative net margin of 37.15% and a positive trailing twelve-month return on equity of 8.44%.
View LivaNova's earnings history.

LivaNova's stock was trading at $62.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LIVN shares have increased by 33.7% and is now trading at $83.78.
View which stocks have been most impacted by COVID-19.

LivaNova updated its FY 2021 earnings guidance on Monday, September, 13th. The company provided earnings per share guidance of $1.750-$2.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.770. The company issued revenue guidance of -.

4 analysts have issued 12 month target prices for LivaNova's stock. Their forecasts range from $84.00 to $117.00. On average, they expect LivaNova's share price to reach $101.00 in the next year. This suggests a possible upside of 20.6% from the stock's current price.
View analysts' price targets for LivaNova or view top-rated stocks among Wall Street analysts.

47 employees have rated LivaNova CEO Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among LivaNova's employees.

Some companies that are related to LivaNova include Masimo (MASI), Getinge (GNGBY), InMode (INMD), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), ViewRay (VRAY), TransMedics Group (TMDX), Cutera (CUTR), Natus Medical (NTUS), Semler Scientific (SMLR), AxoGen (AXGN), Zynex (ZYXI), Stereotaxis (STXS) and Edap Tms (EDAP).
View all of LIVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

LivaNova's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.22%), Primecap Management Co. CA (8.21%), Barrow Hanley Mewhinney & Strauss LLC (4.53%), State Street Corp (4.02%), Vanguard Group Inc. (2.54%) and Maverick Capital Ltd. (2.34%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends for LivaNova.

LIVN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Diamond Hill Capital Management Inc., UBS Asset Management Americas Inc., Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., Sector Gamma AS, Franklin Resources Inc., and BP PLC. Company insiders that have sold LivaNova company stock in the last year include Daniel Jeffrey Moore, and Marco Dolci.
View insider buying and selling activity for LivaNova or view top insider-selling stocks.

LIVN stock was acquired by a variety of institutional investors in the last quarter, including Sachem Head Capital Management LP, State Street Corp, P Schoenfeld Asset Management LP, Balyasny Asset Management LLC, Northern Trust Corp, Bridger Management LLC, Dimensional Fund Advisors LP, and Greenlight Capital Inc..
View insider buying and selling activity for LivaNova or or view top insider-buying stocks.

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LIVN stock can currently be purchased for approximately $83.78.

LivaNova has a market capitalization of $4.11 billion and generates $934.20 million in revenue each year. The company earns $-345,010,000.00 in net income (profit) each year or $1.27 on an earnings per share basis.

LivaNova employs 4,000 workers across the globe.

The official website for LivaNova is www.livanova.com.

LivaNova is headquartered at 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG.

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 442033250660 or via email at [email protected]